Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 Carcinoma of the Cervix clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07938385
Characterisation of Immunological and Molecular Changes Evolving in Patients Undergoing Radiotherapy (CHIMERA)
Radiotherapy is thought to trigger an immune response, and the particular type of immune response may depend on the biology of individual tumours. By studying changes in the immune response and tumour biology during and after radiotherapy, we will gain a better understanding of how different types of radiotherapy, and different tumour types, affect the immune response. This is important for optimising personalised radiotherapy treatment, including in combination with other immunotherapy agents. There is minimal published data reporting feasibility of the above approach, or to guide power calculations. This means pilot work is needed to establish both feasibility and proof-of principle. The CHIMERA protocol is a non-interventional single site study involving sample collection (blood and tumour samples) from patients before, during and after radiotherapy. A maximum of four tumour research biopsies are further optional research samples. The primary and secondary objectives of the CHIMERA protocol are to establish feasibility of longitudinal characterisation of firstly the immune response, and secondly tumour biology before, during and after radiotherapy. Any patient receiving radiotherapy at The Royal Marsden NHS Trust is eligible for CHIMERA provided they are able to provide informed consent, attend follow up appointments and do not have an immunosuppressive infection. If feasibility criteria are met for profiling of the immune response and tumour, CHIMERA will provide both preliminary data and proof-of-principle for larger studies in single tumour sites. CHIMERA is sponsored by the Institute of Cancer Research, LONDON. Funding is also provided by the Institute of Cancer Research.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-16
NCT05461430
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
Gender: All
Ages: 18 Years - Any
Updated: 2026-04-13
1 state